HC Wainwright reiterated their buy rating on shares of Unum Therapeutics (NASDAQ:UMRX) in a research note released on Tuesday morning, AnalystRatings.com reports.
“Our price target of $18/share is based on an equally-weighted composite of: (a) $18.0/share, as a 25x multiple of taxed and diluted $7.63 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.5/share (discounted cash flow analysis using a 18.0% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”,” the firm’s analyst commented.
Several other research analysts have also weighed in on the stock. ValuEngine raised shares of Unum Therapeutics from a hold rating to a buy rating in a report on Thursday, August 1st. Zacks Investment Research raised shares of Unum Therapeutics from a hold rating to a buy rating and set a $4.00 price objective for the company in a report on Friday, April 26th. Finally, SunTrust Banks decreased their price objective on shares of Unum Therapeutics to $6.00 and set a buy rating for the company in a report on Wednesday, July 3rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $12.40.
Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.34) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. The company had revenue of $3.14 million during the quarter, compared to analyst estimates of $3.10 million. Unum Therapeutics had a negative net margin of 340.49% and a negative return on equity of 75.60%. On average, sell-side analysts expect that Unum Therapeutics will post -1.25 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers acquired a new position in shares of Unum Therapeutics in the 1st quarter valued at about $85,000. Susquehanna International Group LLP acquired a new position in shares of Unum Therapeutics in the 2nd quarter valued at about $62,000. Acadian Asset Management LLC boosted its holdings in shares of Unum Therapeutics by 134.8% in the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock valued at $85,000 after buying an additional 18,717 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Unum Therapeutics by 251.5% in the 4th quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock valued at $204,000 after buying an additional 33,091 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Unum Therapeutics in the 2nd quarter valued at about $132,000. 47.16% of the stock is owned by institutional investors and hedge funds.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Featured Article: Understanding Analyst Ratings
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.